Literature DB >> 16917493

Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.

Lixin Zhou1, David Askew, Caiyun Wu, Anita C Gilliam.   

Abstract

The molecular mechanisms governing skin fibrosis in murine sclerodermatous graft-versus-host disease (Scl GVHD) are not known. We used Affymetrix DNA microarrays representing >14,000 mouse genes to characterize global gene expression in skin during development of Scl GVHD in lethally irradiated BALB/c (H-2d) mice transplanted with B10.D2 (H-2d) bone marrow and spleen cells. These mice develop skin thickening, whereas control mice transplanted with syngeneic BALB/c (H-2d) bone marrow and spleen cells do not develop disease. We found consistent differences between mice with Scl GVHD and controls in cytokine messenger RNAs (mRNAs) for both Th1-like (IFN-gamma) and Th2-like (IL-6, Il-10, and IL-13) inflammatory patterns. mRNAs for chemokines CCL2, CCL5, CCL17, IFN-gamma inducible chemokines (CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC), and for growth factors such as platelet-derived growth factor-c, connective tissue growth factor, fibroblast growth factor 1, epidermal growth factor, nerve growth factor-beta, vascular endothelial growth factor (VEGF)-alpha, and VEGF-beta were elevated, similar to human scleroderma. mRNAs for cell adhesion molecules, such as L-selectin (selectin lymphocyte), P-selectin (selectin platelet), E-selectin (selectin endothelium), and vascular cell adhesion molecule 1, were also upregulated. In separate experiments, we confirmed the increased synthesis of IFN-gamma and IL-2, unchanged IL-10, and absence of tumor necrosis factor-alpha, and IL-4 proteins by flow cytometry of isolated skin T cells. These constellations of immunologic changes provide a "fingerprint" for fibrosing autoimmune disease. They are useful to understand the pathogenesis of Scl GVHD, to identify markers for early diagnosis of disease, and to devise more effective strategies for intervention in early scleroderma and Scl GVHD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917493     DOI: 10.1038/sj.jid.5700517

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  23 in total

1.  Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model.

Authors:  Florence Morin; Niloufar Kavian; Wioleta Marut; Christiane Chéreau; Olivier Cerles; Philippe Grange; Bernard Weill; Carole Nicco; Frédéric Batteux
Journal:  J Invest Dermatol       Date:  2015-05-04       Impact factor: 8.551

Review 2.  [Pathogenesis of systemic sclerosis].

Authors:  M Fabri; T Krieg
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

Review 3.  Myeloid Populations in Systemic Autoimmune Diseases.

Authors:  María Morell; Nieves Varela; Concepción Marañón
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

4.  Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease.

Authors:  Sydney X Lu; Amanda M Holland; Il-Kang Na; Theis H Terwey; Onder Alpdogan; Jhoanne L Bautista; Odette M Smith; David Suh; Christopher King; Adam Kochman; Vanessa M Hubbard; Uttam K Rao; Nury Yim; Chen Liu; Alvaro C Laga; George Murphy; Robert R Jenq; Johannes L Zakrzewski; Olaf Penack; Lindsay Dykstra; Kevin Bampoe; Lia Perez; Bruce Furie; Barbara Furie; Marcel R M van den Brink
Journal:  J Immunol       Date:  2010-07-09       Impact factor: 5.422

5.  Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets.

Authors:  Matthew B Greenblatt; Jennifer L Sargent; Giuseppina Farina; Kelly Tsang; Robert Lafyatis; Laurie H Glimcher; Michael L Whitfield; Antonios O Aliprantis
Journal:  Am J Pathol       Date:  2012-01-11       Impact factor: 4.307

6.  STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model.

Authors:  Vedran Radojcic; Maria A Pletneva; Hung-Rong Yen; Sanja Ivcevic; Angela Panoskaltsis-Mortari; Anita C Gilliam; Charles G Drake; Bruce R Blazar; Leo Luznik
Journal:  J Immunol       Date:  2009-12-07       Impact factor: 5.422

7.  Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.

Authors:  Kathryn J Martires; Kristin Baird; Seth M Steinberg; Lana Grkovic; Galen O Joe; Kirsten M Williams; Sandra A Mitchell; Manuel Datiles; Fran T Hakim; Steven Z Pavletic; Edward W Cowen
Journal:  Blood       Date:  2011-07-26       Impact factor: 22.113

8.  Adenosine A₂A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease.

Authors:  Kyu Lee Han; Stephenie V M Thomas; Sherry M Koontz; Cattlena M Changpriroa; Seung-Kwon Ha; Harry L Malech; Elizabeth M Kang
Journal:  J Immunol       Date:  2012-12-07       Impact factor: 5.422

Review 9.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

Review 10.  Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients.

Authors:  C Fiuza-Luces; R J Simpson; M Ramírez; A Lucia; N A Berger
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.